<DOC>
	<DOCNO>NCT00429416</DOCNO>
	<brief_summary>The purpose research study determine experimental agent , LLME decrease incidence severity Graft-Versus-Host-Disease ( GVHD ) follow blood ( hematopoietic ) stem cell transplantation</brief_summary>
	<brief_title>Research Study Determine Experimental Agent , LLME Can Decrease Incidence Severity Graft-Versus-Host-Disease ( GVHD ) Following Blood ( Hematopoietic ) Stem Cell Transplantation</brief_title>
	<detailed_description>We believe risk allogeneic transplant drastically reduce follow criterion meet : ( 1 ) consistent engraftment , ( 2 ) little GVHD ability rapidly withdraw immune suppression , ( 3 ) rapid recovery CD4 count level great 200 cells/micro liter . Our prior ( ongoing ) trial attempt address LLME treat T cell give donor lymphocyte infusion ( DLI ) address point 2 3 . The current study address treatment CD34- fraction graft attempt address point 1 2 ( less extent point 3 ) . We believe point consistently achieve mortality allogeneic HSCT may reduce level akin autologous HSCT . We propose test hypothesis LLME-treated T cell safe regard reduce GVHD infusion relate toxicity administration part transplant facilitate engraftment . We believe approach ultimately important step variety transplant setting range matched sibling haplodisparate donor .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients must &gt; 18 year age , upper age limit . Patients must ECOG performance status 0 1 . Any patient hematologic malignancy unlikely cure conventional treatment eligible study . Patients disease specific protocol exists transplant protocol discuss introduction . Patients prior autograft may treat protocol . Patients must adequate physical function measure follow criterion : Cardiac : Asymptomatic , symptomatic , leave ventricular ejection fraction rest must &gt; 40 % . Hepatic : Aspartate transaminase ( AST ) micro 3x upper limit normal total serum bilirubin &lt; 2.5 mg/dL . Patients high bilirubin `` benign condition '' Gilbert 's disease may still eligible study . Renal : Serum creatinine within normal range creatinine outside normal range creatinine clearance &gt; 60 ml/min/1.73m2 . Serum creatinine must less equal 2.0 mg/dl . Pulmonary : Asymptomatic , symptomatic , DLCO ( diffusion capacity ) &gt; 45 % predict ( correct hemoglobin ) The patient guardian ( ) must able give informed consent study . Patient must suitable donor identical HLA ( human leukocyte antigen ) A , B , C , DR . Single antigen mismatch HLAA , B , C , DR also permit . Donors obtain National Marrow Donor Program ( NMDP ) follow NMDP guideline . Patients eligible standard myeloablative transplant standard myeloablative transplant preferable treat protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hematologic Malignancies</keyword>
	<keyword>GVHD</keyword>
	<keyword>Graft-Versus-Host-Disease</keyword>
	<keyword>LLME</keyword>
	<keyword>CD34+ stem cell infusion</keyword>
	<keyword>CD34- fraction</keyword>
	<keyword>Cyclosporine</keyword>
	<keyword>Mycophenolate Mofetil</keyword>
	<keyword>HSCT</keyword>
	<keyword>Hematopoietic stem cell transplantation</keyword>
</DOC>